Skip to main content

Table 1 Descriptive analysis of variables according to the three levels

From: Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer

  Mean (SD) or n (%) Endocrine therapy adherence (MMAS)
Mean (SD) r t or F p
Total MMAS score   6.36 (1.65)    
Demographic/medical
 Age 50.31 (9.03)   .136   .050
 Education level College above 84 (40.8) 6.12 (1.64)   1.64 .197
High 90 (43.7) 6.50 (1.56)
Below high 32 (15.5) 6.63 (1.89)
 Marital status No 20 (9.6) 6.20 (1.35)   −.473 .637
Yes 189 (90.4) 6.38 (1.68)
 Employment status No 117 (56.5) 6.48 (1.57)   1.103 .271
Yes 90 (43.5) 6.23 (1.75)
 FAM HX of breast cancer No 191 (91.0) 6.36 (1.69)   −.028 .975
Yes 19 (9.0) 6.37 (1.16)  
 FAM HX of other cancer No 127 (60.5) 6.44 (1.64)   .856 .393
Yes 83 (39.5) 6.24 (1.66)  
 Cancer stage Stage 1–3 184 (87.6) 6.47 (1.59)   2.554 .011
Stage 0 26 (12.4) 5.60 (1.89)  
 Node meta Negative 145 (69.0) 6.27 (1.68)   −1.221 .223
Positive 65 (31.0) 6.57 (1.57)  
 Type of surgery Mastectomy 27 (12.9) 6.71 (1.37)   1.200 .232
Conservation 183 (87.1) 6.31 (1.68)
 RT No 33 (15.7) 6.39 (1.60)   −.135 .893
Yes 177 (84.3) 6.35 (1.66)
 CT No 110 (52.4) 6.28 (1.68)   .705 .481
Yes 100 (47.6) 6.44 (1.61)
 AET regimen AI 47 (22.4) 6.79 (1.54)   2.068 .040
SERM 163 (77.6) 6.23 (1.66)  
 Months on ET   26.75 (19.79)   −.012   .858
 FSH level   21.83 (24.31)   .160   .100
General psychological
 Menopause-related symptom (0–44) 13.32 (7.71)   −.087   .214
 Depression (0–60) 15.56 (9.83)   −.204   .004
 Fear of progression (12–60) 31.60 (10.79)   −.053   .458
Endocrine therapy-specific
 Beliefs about AET (10–50) 24.50 (6.47)   −.005   .945
 Necessity beliefs (5–25) 13.83 (4.17)   .235   .001
 Concern beliefs (5–25) 10.68 (4.10)   −.247   .000
 Self-efficacy (0–40) 28.99 (4.41)   .187   .007
  1. MMAS Morisky Medication Adherence Scale, FAM HX family history, RT radiotherapy, CT chemotherapy, AI aromatase inhibitor, SERM selective estrogen receptor modulator, ET endocrine therapy, FSH follicle-stimulating hormone. Permission for MMAS-8 was obtained from Dr. Morisky and MMAS Research. The Morisky Widget, MMAS-8 and MMAS-4, are protected by US and International Trademark and Copyright laws. Permission for use is required. A license agreement is available from: MMAS Research LLC 14725 NE 20th St. Bellevue WA 98007